Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder Cancer
Bladder cancer accounts for nearly 200,000 deaths worldwide yearly. Urothelial carcinoma (UC) accounts for nearly 90% of cases of bladder cancer. Cisplatin-based chemotherapy has remained the mainstay of treatment in the first-line setting for locally advanced or metastatic UC. More recently, the tr...
Saved in:
Main Authors: | David J. Benjamin, Yung Lyou |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/26625f45f9874fcfa537b6f572bfa57c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TGF-β Signaling and Resistance to Cancer Therapy
by: Maoduo Zhang, et al.
Published: (2021) -
A review on the evolution of immunotherapy in bladder carcinoma
by: Milena Gulinac, et al.
Published: (2020) -
CRTAC1 (Cartilage acidic protein 1) inhibits cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) process in bladder cancer by downregulating Yin Yang 1 (YY1) to inactivate the TGF-β pathway
by: Jianghua Yang, et al.
Published: (2021) -
Lymphoepithelioma-Like Carcinoma of Urinary Bladder with Diagnostic Dilemma: Case Report of A Rare Variant of Urothelial Carcinoma
by: Swati Saini, et al.
Published: (2021) -
GPR37 promotes the malignancy of lung adenocarcinoma via TGF-β/Smad pathway
by: Wang Jian, et al.
Published: (2020)